Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth hormone angiogenic effect study in lower limb critical ischemia (GHAS)
2012-002228-34Phase 3Active
- Sponsor
- Diego Caicedo Valdés
- Start
- Sep 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of somatropin in chronic limb-threatening ischemia (CLTI) and arteriosclerosis obliterans, sponsored by Diego Caicedo Valdés. Primary endpoint: Photoplethysmography waveform amplitude. Started Sep 2012; status: active.
02
Drugs
somatropin
03
Conditions
chronic limb-threatening ischemia (CLTI)arteriosclerosis obliterans
Beyond the preview
Go deeper on 2012-002228-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002228-34.